National Pharmaceutical Law Firm Investigates Legal Action Against Biogen Idec and Elan, Makers of Tysabri
Houston, TX — Blizzard & Nabers, LLC, one of the nation's leading pharmaceutical litigation firms, is investigating legal action against Biogen Idec and Elan, the makers of the dangerous drug Tysabri (natalizumab), a medication used to treat multiple sclerosis patients.
On behalf of an Indiana-based client, the firm is investigating legal recourse for patients diagnosed with progressive multifocal leukoencephalopathy (PML) after taking Tysabri.
PML, a debilitating and sometimes fatal neurological condition, destroys the myelin sheath covering the axons of nerve cells and impairs the transmission of nerve impulses, often leading to severe disability or death. Patients experience vision loss, impaired speech, paralysis and cognitive deterioration.
Tysabri was fast-track approved by the FDA in 2004, but withdrawn from the market after being linked to PML in 2005. The drug was reintroduced in 2006 with a black box warning for PML, but the number of Tysabri-treated patients contracting PML continues to rise. To date, 70 Tysabri-treated patients have contracted PML; 14 have died and dozens more are severely disabled.
"When you consider that Tysabri causes PML which results in either death or severe brain damage, and that the risk of contracting PML increases each month that a patient takes the drug, it is difficult to understand why the FDA allows it to remain on the market," said Blizzard, “We will continue to investigate and may seek justice on behalf of these suffering patients.”
The FDA warning notes that the risk of developing PML increases over time, although Biogen seriously minimized those risks in its marketing materials. The company’s questionable marketing practice led to a warning letter from the FDA earlier this year.
Patients taking Tysabri who develop the debilitating symptoms of PML may consider legal action against the pharmaceutical company and should contact Blizzard & Nabers for more information. MS patients should also know that there are safe, effective alternatives to Tysabri on the market.
Patients who have taken Tysabri may get more information about their risks and potential remedies by visiting a special Tysabri information page, at:
About Ed Blizzard
Ed Blizzard is the founding partner of Blizzard & Nabers, one of the nation's leading pharmaceutical litigation firms. Representing thousands of clients harmed by dangerous drugs and medical devices, his firm has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical. As one of the most successful litigation attorneys in the country, Mr. Blizzard has been a major player in some of the nation's largest pharmaceutical injury verdicts and settlements. His successful handling of the historic cases against Vioxx, Ephedra and Digitek, and his service as chief negotiator in the landmark 1998 breast implant settlement with Dow Corning have solidified Blizzard's position as one of the most effective attorneys in mass tort litigation.